Freedom Broker analyst Ilya Zubkov upgraded Intensity Therapeutics (INTS) to Buy from Hold with a price target of $20, down from $37.50. The firm says the company’s new financing has enabled the restart of INVINCIBLE-4 enrollment. It cites the longer than expected study timeline for the target cut but valuation for the upgrade.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INTS:
- U.S. Tariff and Trade Policy Risks Threaten Intensity Therapeutics’ Supply Chain, Costs, and Stock Valuation
- Intensity Therapeutics issued new patent in the US
- Intensity Therapeutics Expands ATM Equity Offering Capacity
- Intensity Therapeutics price target adjusted to $30 at Alliance Global
- Intensity Therapeutics provides update on INVINCIBLE-4 Study